+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 197 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.

Age: 18Years +All GendersPhase 1Phase 2
77 locations
O

Actively Recruiting

Researchers are conducting a long-term observational study called POS-ARI-PC to understand acute respiratory infections ARI in adults and children who visit primary care facilities across Europe. The study aims to describe how ARI presents and is managed, including infections caused by known and emerging respiratory pathogens. It also seeks to build a research infrastructure to support future clinical studies on the treatment, diagnosis, and prevention of ARI in primary care. The study includes two main protocols POS-ARI-PC AUDIT and POS-ARI-PC CORE. The AUDIT protocol collects anonymous annual data from about 2,000 patients with ARI across Europe to describe patient presentations and care. The CORE protocol is a prospective observational study where patients with ARI undergo specific sampling and are followed for 28 days to capture infection causes and clinical outcomes. Embedded studies, such as POS-ARI-PC-001 focused on respiratory infections in older adults, are added to this platform with detailed appendices. Participants provide consent and complete questionnaires about their symptoms and experiences. They give combined throat and nose swabs for infection analysis and complete daily diaries for up to 14 days. Follow-up after 28 days collects information on consultations and hospital referrals. Some participants may join optional interviews to share their views. Researchers measure outcomes including illness severity, recovery, medication use, complications, and variations in care, aiming to improve understanding and readiness for future trials. The study runs until August 2027.

All AgesAll Genders
3 locations
O

Actively Recruiting

Researchers are evaluating a new classification system called the Modified Baveno Classification to better understand obstructive sleep apnoea OSA in adults newly diagnosed with this condition. The study aims to monitor long-term improvements in both objective and subjective measures related to OSA, including daytime sleepiness and cardiovascular health. This observational cohort study is led by Wissenschaftliches Institut Bethanien e.V and focuses on patients aged 40 years and older. Participants will be categorized into three groups based on the Baveno classification those for whom OSA-specific treatment is generally not recommended, those for whom treatment should be considered individually, and those for whom treatment is generally recommended. The study does not involve administering treatments but observes the patients over time according to their classification and treatment indications. During the study, participants will be followed for up to 36 months. Researchers will assess changes in daytime sleepiness using the Epworth Sleepiness Scale and monitor office blood pressure. Additional evaluations include cardiovascular events, treatment usage, insomnia severity, sleep length, fatigue, cognitive performance, and overnight oxygen levels. The study tracks these measures throughout the observation period to understand how the classification correlates with patient outcomes and treatment decisions.

Age: 40Years +All Genders
18 locations
E

Actively Recruiting

Researchers are studying STXBP1-related disorders STXBP1-RD, which are rare genetic neurodevelopmental conditions causing developmental delays, intellectual disability, seizures, behavioral problems, and movement disorders. These disorders vary widely in severity and significantly affect patients and caregivers quality of life. Currently, there is no cure, and treatments mainly focus on controlling symptoms. This European collaborative study aims to better understand the natural history, identify disease modifiers, relevant clinical endpoints, and outcome measures to prepare for future clinical trials of new precision therapies. The study involves a large-scale, pan-European natural history study composed of two phases a 12-month pilot natural history study pNHS and a 4-year extension natural history study eNHS. Researchers will collect both retrospective and prospective data on demographics, genetics, and clinical features from patients with STXBP1-RD. The pilot phase will assess the sensitivity of outcome measures to detect differences in impairment and changes over time, as well as the burden of study participation for patients and caregivers. Participants will be followed over different life stages including infancy, childhood, adolescence, and adulthood. Assessments include clinical evaluations and patient and caregiver input to capture the diseases impact and unmet needs. The primary outcome measure is changes in clinical assessment percentiles over 12 months. This comprehensive data collection will support the development of relevant endpoints and biomarkers for future clinical trials, with the overall participation lasting up to several years depending on the study phase.

All AgesAll Genders
1 location
P

Actively Recruiting

Researchers are evaluating Enzomenib DSP-5336, an oral drug, in patients with various types of acute leukemia, including relapsed or refractory acute myeloid leukemia AML, acute lymphocytic leukemia ALL, and acute leukemia of ambiguous lineage. The study also includes patients with high-risk myelodysplastic syndromes MDS and relapsed multiple myeloma MM in selected sites. This phase 12 trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of DSP-5336 alone or combined with standard AML treatments, particularly in patients with specific genetic mutations like MLL rearrangement or NPM1 mutation. The study involves dose escalation and dose expansion of DSP-5336 administered orally. Participants may receive DSP-5336 alone or combined with standard AML regimens such as venetoclax plus azacitidine or intensive chemotherapy with cytarabine and daunorubicin 73. Different study arms include patients with or without certain medications like CYP3A4 inhibitor azoles, and those with specific genetic profiles. The trial evaluates recommended phase 2 doses for various patient groups and combination treatments. Participants will undergo assessments including monitoring for adverse events within 30 days after the last dose and evaluation of clinical responses approximately six months after treatment begins. Researchers will collect blood and bone marrow samples for genomic analysis and track drug levels in the body. Safety labs, ECGs, physical exams, and patient questionnaires will be performed throughout the study. The trial includes long-term follow-up of overall survival up to two years after treatment ends, with visits and tests scheduled to monitor health and treatment effects.

Age: 12Years +All GendersPhase 1Phase 2
104 locations
P

Actively Recruiting

Researchers are evaluating a new medication called VH4524184 for treating adults with HIV-1 who have never received treatment before. This Phase 2b study compares two doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide FTCTAF, against a standard HIV treatment combining dolutegravir and lamivudine DTG3TC. The goal is to collect long-term data on the antiviral activity of VH4524184 and to understand the best dosing for future studies. Participants are assigned to one of several groups one group receives a low dose of VH4524184 plus FTCTAF daily for 12 months, another group receives a high dose of VH4524184 plus FTCTAF daily for 12 months, and a third group takes DTG and 3TC daily for 24 months. After 12 months, those on VH4524184 may continue with a selected dose combined with FTCTAF daily until month 24. All medications are taken orally. During the study, participants attend scheduled visits for assessments including blood tests to measure HIV-1 RNA levels, CD4 T-cell counts, and drug concentrations. Researchers monitor the percentage of participants achieving viral suppression at 12 months and maintain it through 24 months. Safety is closely observed through tracking adverse events until roughly month 36. The total participation time may span up to 36 months to evaluate the long-term effects and safety of the treatments.

Age: 18Years +All GendersPhase 2
123 locations
O

Actively Recruiting

Researchers are evaluating the safety and performance of the ORIGIN4 CR cruciate retaining devices used in total knee replacement surgery. This observational study aims to measure the safety by tracking the proportion of patients needing revision surgery one year after the procedure and to assess performance using the Knee Society Score KSS both for the knee and function at one year. The hypothesis is that patients will notice a significant natural feel improvement in the prosthesis within the first year, with slight further gains at two years, along with better overall satisfaction. The study will include 199 patients who will receive treatment with the ORIGIN4 CR devices and associated instruments. Patients will be enrolled over an 18-month period and followed for 24 months. This single-arm study does not include a comparison group and will monitor patients up to two years after their surgery to assess outcomes. Participants will be asked to attend follow-up visits at one and two years after their surgery. During these visits, researchers will evaluate safety through revision rates and assess performance using the Knee Society Score and Function Score, patient satisfaction surveys, and the Forgotten Joint Score questionnaire. The study focuses on understanding quality of life and prosthesis function after total knee replacement with the ORIGIN4 CR device.

Age: 18Years - 99YearsAll Genders
2 locations
P

Actively Recruiting

Researchers are studying an investigational drug called linvoseltamab in adults who have a moderate risk of developing multiple myeloma. This group includes patients with precancerous conditions known as High-Risk Monoclonal Gammopathy of Undetermined Significance HR-MGUS and Non-High-Risk Smoldering Multiple Myeloma NHR-SMM. The main goal is to understand how well linvoseltamab can eliminate abnormal plasma cells and laboratory signs associated with these conditions. Participants will receive linvoseltamab following a step-up dosing regimen to assess safety and tolerability before moving to one of four full dosing regimens. The study is divided into a safety run-in phase and an expansion phase where participants are assigned to different dose groups without randomization. Linvoseltamab is given according to the study protocol, with dosing schedules designed to monitor effects and side effects. During the study, participants will be closely monitored through regular safety observations over 35 days and longer-term assessments up to 5.5 years. Researchers will track adverse events, treatment responses including complete response rates, laboratory results, and the presence of antibodies against the drug. Blood levels of linvoseltamab are measured up to 9 months. This comprehensive monitoring will help understand the drugs impact and safety over time.

Age: 18Years +All GendersPhase 2
39 locations
R

Actively Recruiting

Researchers are evaluating a new approach to selecting biologic treatments for adults with active Crohns Disease CD. This prospective, randomized study compares standard treatment selection to a method guided by epigenetic markers, aiming to assess which method better induces clinical remission and improves endoscopic response. The trial includes patients who are either new to biologic therapy or have used no more than one prior biologic treatment. The study is designed to measure efficacy, safety, and cost-effectiveness of this epigenome-guided approach. Participants are randomly assigned to one of two groups one receives biologic therapy based on epigenetic testing results using a specialized software called EpiPredict, which predicts response to two biologics, Vedolizumab VDZ or Ustekinumab UST. The other group receives biologic treatment chosen by their doctor following usual care guidelines without epigenetic information. Both groups receive their biologic treatments as labeled, with dosing adjustments allowed as needed by the treating physician. Throughout the 26-week treatment phase, participants undergo clinical assessments aligned with their biologic treatment schedules. Follow-up visits continue every six months up to two years, collecting data from medical records and online questionnaires. Researchers will measure clinical remission, endoscopic response, and cost-effectiveness among other outcomes to determine the value of using epigenetic markers in treatment selection for Crohns Disease.

Age: 18Years +All GendersPhase Not Applicable
51 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of two chemotherapy combinations, 5-FU with nanoliposomal irinotecan NALIRI and 5-FU with nanoliposomal irinotecan plus oxaliplatin NALIRINOX, in patients with metastatic pancreatic ductal adenocarcinoma PDAC who have progressed after treatment with Gemcitabine-Abraxane or Gemcitabine alone. This phase 2 randomized study aims to assess the progression-free survival rate and safety of these treatments in fit patients with good performance status. Participants receive treatment in 14-day cycles. In the NALIRI group, patients are given leucovorin, nanoliposomal irinotecan at 70 mgm, and 5-FU through intravenous infusion. The NALIRINOX group receives oxaliplatin, leucovorin, nanoliposomal irinotecan at 50 mgm, and 5-FU. The study monitors dosing adjustments based on individual tolerance, especially for patients with specific genetic markers. Treatments are administered mostly via intravenous infusions over several hours and continuous infusions over two days. During the study, participants undergo regular imaging scans, tumor marker tests, and safety assessments to evaluate treatment response and side effects. Researchers track progression-free survival at day 85 post-randomization and continue monitoring survival and disease control for up to five years. Safety is closely followed through laboratory tests, physical exams, and adverse event reporting until two weeks after treatment ends. The total participation time varies depending on individual treatment response and follow-up duration.

Age: 18Years +All GendersPhase 2
13 locations

1-10 of 197

1